Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Current Assets: 2020-2025

Historic Current Assets for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to $184.1 million.

  • Foghorn Therapeutics' Current Assets fell 32.12% to $184.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $184.1 million, marking a year-over-year decrease of 32.12%. This contributed to the annual value of $249.6 million for FY2024, which is 3.92% up from last year.
  • Per Foghorn Therapeutics' latest filing, its Current Assets stood at $184.1 million for Q3 2025, which was down 9.68% from $203.8 million recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Current Assets high stood at $459.6 million for Q4 2021, and its period low was $124.0 million during Q3 2021.
  • Its 3-year average for Current Assets is $250.2 million, with a median of $249.6 million in 2024.
  • As far as peak fluctuations go, Foghorn Therapeutics' Current Assets skyrocketed by 204.76% in 2022, and later plummeted by 34.04% in 2024.
  • Foghorn Therapeutics' Current Assets (Quarterly) stood at $459.6 million in 2021, then dropped by 23.54% to $351.4 million in 2022, then tumbled by 31.65% to $240.2 million in 2023, then climbed by 3.92% to $249.6 million in 2024, then tumbled by 32.12% to $184.1 million in 2025.
  • Its Current Assets stands at $184.1 million for Q3 2025, versus $203.8 million for Q2 2025 and $225.4 million for Q1 2025.